Fig 4 - حسب Michelle Gelippi (9580022)

Functional feature prediction of intestinal microbiota from healthy (blue) and diseased (orange) shrimp. حسب Lalitphan Kitsanayanyong (19353505)

الموضوعات:

Post-mortem lesions of chickens with decreased egg production in Yancheng in 2023. حسب Yan Wang (15435)

Hypothesis that explains and predicts expansion of ages of KD due to decreased IgG levels. حسب Hiromi Yamaguchi (2396248)

الموضوعات:

Significant mutations in RAD52, BRCA2, BRCA1 and PALB2. حسب Abdulaziz B. Hamid (13804692)

Cabozantinib significantly decreases tumor volume and prolongs survival in SCNPC PDX models. حسب Mark P. Labrecque (10011469)

Significant decrease of the viability of A375 melanoma cells after CD treatment. حسب Lena Berning (7430117)

Arctigenin decreased proliferation in colorectal cancer cells with no significant effect on normal cells. حسب Xiang-Fan Chen (13932983)

AME (95% CI) of US and EU FTA participation on predicted probability of unhealthy commodity policy implementation. حسب Pepita Barlow (3822556)

Data frame showing the predictive changes in composition and the predicted change in depressive symptoms. حسب Hugues Sampasa-Kanyinga (606145)

Main fixed effects of interest within LMEs predicting internalizing and externalizing problems. حسب Irina Jarvers (10704223)

الموضوعات:

Model comparisons of linear-mixed effect models predicting internalizing and externalizing problems. حسب Irina Jarvers (10704223)

الموضوعات:

Flow diagram of the study. حسب Yoonjee Cho (15453454)

"…Based on the AUT, the patients were divided into a high-decrease group (n = 156) and a low-decrease group (n = 240). …"

Baseline characteristics of patients. حسب Yoonjee Cho (15453454)

"…Based on the AUT, the patients were divided into a high-decrease group (n = 156) and a low-decrease group (n = 240). …"

DataSheet4_Overall Survival Prediction of Advanced Cancer Patients by Selection of the Most Significant Baseline Serum Biomarker Combination.pdf حسب Daniel Deme (12023909)

"…Based on assessed biomarker cut-offs, four patient groups were created to determine whether biomarker values were out of range (ORV) compared to cut-off: 1) No ORV biomarkers (n = 24; OS = 26.07 months); 2) one ORV biomarker (n = 21; OS = 13.50 months); 3) two ORV biomarkers (n = 20; OS = 7.97 months), and 4) three ORV biomarkers (n = 10; OS = 3.91 months). …"

DataSheet3_Overall Survival Prediction of Advanced Cancer Patients by Selection of the Most Significant Baseline Serum Biomarker Combination.csv حسب Daniel Deme (12023909)

"…Based on assessed biomarker cut-offs, four patient groups were created to determine whether biomarker values were out of range (ORV) compared to cut-off: 1) No ORV biomarkers (n = 24; OS = 26.07 months); 2) one ORV biomarker (n = 21; OS = 13.50 months); 3) two ORV biomarkers (n = 20; OS = 7.97 months), and 4) three ORV biomarkers (n = 10; OS = 3.91 months). …"

DataSheet4_Overall Survival Prediction of Advanced Cancer Patients by Selection of the Most Significant Baseline Serum Biomarker Combination.pdf حسب Daniel Deme (12023909)

"…Based on assessed biomarker cut-offs, four patient groups were created to determine whether biomarker values were out of range (ORV) compared to cut-off: 1) No ORV biomarkers (n = 24; OS = 26.07 months); 2) one ORV biomarker (n = 21; OS = 13.50 months); 3) two ORV biomarkers (n = 20; OS = 7.97 months), and 4) three ORV biomarkers (n = 10; OS = 3.91 months). …"

DataSheet3_Overall Survival Prediction of Advanced Cancer Patients by Selection of the Most Significant Baseline Serum Biomarker Combination.csv حسب Daniel Deme (12023909)

"…Based on assessed biomarker cut-offs, four patient groups were created to determine whether biomarker values were out of range (ORV) compared to cut-off: 1) No ORV biomarkers (n = 24; OS = 26.07 months); 2) one ORV biomarker (n = 21; OS = 13.50 months); 3) two ORV biomarkers (n = 20; OS = 7.97 months), and 4) three ORV biomarkers (n = 10; OS = 3.91 months). …"

DataSheet2_Overall Survival Prediction of Advanced Cancer Patients by Selection of the Most Significant Baseline Serum Biomarker Combination.csv حسب Daniel Deme (12023909)

"…Based on assessed biomarker cut-offs, four patient groups were created to determine whether biomarker values were out of range (ORV) compared to cut-off: 1) No ORV biomarkers (n = 24; OS = 26.07 months); 2) one ORV biomarker (n = 21; OS = 13.50 months); 3) two ORV biomarkers (n = 20; OS = 7.97 months), and 4) three ORV biomarkers (n = 10; OS = 3.91 months). …"

DataSheet1_Overall Survival Prediction of Advanced Cancer Patients by Selection of the Most Significant Baseline Serum Biomarker Combination.pdf حسب Daniel Deme (12023909)

"…Based on assessed biomarker cut-offs, four patient groups were created to determine whether biomarker values were out of range (ORV) compared to cut-off: 1) No ORV biomarkers (n = 24; OS = 26.07 months); 2) one ORV biomarker (n = 21; OS = 13.50 months); 3) two ORV biomarkers (n = 20; OS = 7.97 months), and 4) three ORV biomarkers (n = 10; OS = 3.91 months). …"